Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (10941)	11/10/1997 9:19:00 AM
From: chirodoc	Respond to of 32384

<<<<<<< I expect off-label Targretin sales to be significant. .........it is with many popular meds and with the broad range of effects fo targretin i think that you are most likey correct. ......for your info (although it may not matter) i did not sell ligand but bought a bit more on the last drop. :-)

To: Henry Niman who wrote (10941)	11/10/1997 2:17:00 PM
From: Andrew H	Read Replies (2) \| Respond to of 32384

>>By the time Tragretin is approved, LGND should have advanced interim clinical data from Europe as well as North America (for type II diabetes). With FDA reform in place, they will be able to show the interim data to physicians and begin off label sales. Likewise, the drug is in Phase II/III lung cancer trials which is a much bigger market and that data should come out this quarter. I expect off-label Targretin sales to be significant.<< It would seem pretty certain to me that Targretin would receive fast track consideration. I think you are correct that Targretin will be a big seller for diabetes although it may take a while. Doctors may hesitate to throw another drug into the rezulin liver problem equation before extensive testing is done. Still, targretin has been around for quite a while now and safety and side effect data should be considerable.